There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Novavax Inc. (NVAX) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$3.57, or -13.80%, to $22.3. Volume reached 78,300 shares, with price reaching a high of $22.6 and a low of $22.15. Yahoo Finance discussed the stock recently as it posted Novavax Nuvaxovid™ COVID-19 Vaccine Receives Expanded Emergency Use Authorization in Taiwan for Use in Adolescents Aged 12 Through 17.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $22.44 and fluctuated between $24.65 as its day high and $21.83 as its day low. The current market capitalization of Novavax Inc. is $1.88B. A total of 10.69 million shares were traded on the day, compared to an average of 6.09M shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, NVAX has seen 4 BUY and 4 SELL insider trades, representing the acquisition of 4,688 and the disposition of 2,017 shares. Over the last 12 months, there were 56 BUYs and 303 SELLs from insiders. Insiders purchased 282,792 shares during that period but sold 295,657.
In the most recent transaction, YOUNG JAMES F sold 12,500 shares of NVAX for 73.58 per share on Mar 31. After the transaction, the Director now owns 62,590 company shares. In a previous transaction on Jan 03, Herrmann John A III sold 5,000 shares at 140.91 per share. NVAX shares that EVP, Chief Legal Officer owns now total 3,845.
Among the insiders who sold shares, YOUNG JAMES F disposed of 3,750 shares on Dec 31 at a per-share price of $144.16. This resulted in the Director holding 75,090 shares of NVAX after the transaction. In another insider transaction, Herrmann John A III sold 5,000 shares at $230.00 per share on Dec 20. Company shares held by the EVP, Chief Legal Officer now total 3,845.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for NVAX in the last 3 months, the mean price target is $105.83 with high estimates of $207.00 and low estimates of $20.00. In terms of 52-week highs and lows, NVAX has a high of $260.69 and a low of $25.84.
As of this writing, NVAX has an earnings estimate of $4.11 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of $6.95 per share and a lower estimate of $0.93. The company reported an EPS of $-6.53 in the last quarter, which was -218.51% lower than expectations of $5.51.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 8 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NVAX is Overweight with a score of 4.00. A total of 4 analysts rated the stock as Buy while 0 rated it as Overweight while 2 rated it as Hold. Among the other participants, 1 thought the stock was Underweight and 1 thought it should be Sold.